Parkinson's disease is caused by a selective vulnerability and cell loss of dopaminergic
neurons of the Substantia Nigra pars compacta and, consequently, striatal dopamine …

In patients with Parkinson's disease, the therapeutic efficacy of l-DOPA medication is
gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually …

Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …

In a recent issue of Experimental Neurology, Dupre et al. report on a study performed in the
6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) which brings …

Selective activation of 5-HT1 receptors has been shown to produce near to full suppression
of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease; however, a …

Abstract L-3, 4-dihydroxyphenylalanine (L-DOPA) has been the standard treatment for
Parkinson's disease (PD), despite that its chronic use leads to motor fluctuations and …

Long‐term dopamine replacement therapy with l‐DOPA in Parkinson's disease often leads
to the development of abnormal involuntary movements known as l‐DOPA‐induced …

The serotonin system has recently emerged as an important player in the appearance of l-
DOPA-induced dyskinesia (LID) in experimental models of Parkinson's disease, as it …

While serotonin 5-HT1A receptor (5-HT1AR) agonists reduce l-DOPA-induced dyskinesias
(LID) by normalizing activity in the basal ganglia neurocircuitry, recent evidence suggests …

Convergent evidence suggests that serotonin 5-HT1A receptor (5-HT1AR) agonists reduce l-
DOPA-induced dyskinesia by auto-regulating aberrant release of l-DOPA-derived dopamine …